These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 20527725)
1. Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Sen T; Dutta A; Chatterjee A Anticancer Drugs; 2010 Jul; 21(6):632-44. PubMed ID: 20527725 [TBL] [Abstract][Full Text] [Related]
2. Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Sen T; Moulik S; Dutta A; Choudhury PR; Banerji A; Das S; Roy M; Chatterjee A Life Sci; 2009 Feb; 84(7-8):194-204. PubMed ID: 19105967 [TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process. Sen T; Chatterjee A Eur J Nutr; 2011 Sep; 50(6):465-78. PubMed ID: 21170718 [TBL] [Abstract][Full Text] [Related]
4. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Farabegoli F; Papi A; Orlandi M Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926 [TBL] [Abstract][Full Text] [Related]
5. Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. Maity G; Choudhury PR; Sen T; Ganguly KK; Sil H; Chatterjee A Tumour Biol; 2011 Feb; 32(1):129-38. PubMed ID: 20821288 [TBL] [Abstract][Full Text] [Related]
6. EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion. Farabegoli F; Govoni M; Spisni E; Papi A Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28465354 [TBL] [Abstract][Full Text] [Related]
7. Laminin induces matrix metalloproteinase-9 expression and activation in human cervical cancer cell line (SiHa). Maity G; Sen T; Chatterjee A J Cancer Res Clin Oncol; 2011 Feb; 137(2):347-57. PubMed ID: 20425121 [TBL] [Abstract][Full Text] [Related]
8. (-)-Epigallocatechin-3-gallate inhibits invasion and migration of salivary gland adenocarcinoma cells. Park JH; Yoon JH; Kim SA; Ahn SG; Yoon JH Oncol Rep; 2010 Feb; 23(2):585-90. PubMed ID: 20043125 [TBL] [Abstract][Full Text] [Related]
9. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity. Kim SO; Kim MR Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610 [TBL] [Abstract][Full Text] [Related]
10. (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells. Kim M; Murakami A; Kawabata K; Ohigashi H Carcinogenesis; 2005 Sep; 26(9):1553-62. PubMed ID: 15860507 [TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin-3-gallate inhibits proliferation and migration of human colon cancer SW620 cells in vitro. Zhou F; Zhou H; Wang T; Mu Y; Wu B; Guo DL; Zhang XM; Wu Y Acta Pharmacol Sin; 2012 Jan; 33(1):120-6. PubMed ID: 22101170 [TBL] [Abstract][Full Text] [Related]
12. CADPE inhibits PMA-stimulated gastric carcinoma cell invasion and matrix metalloproteinase-9 expression by FAK/MEK/ERK-mediated AP-1 activation. Han H; Du B; Pan X; Liu J; Zhao Q; Lian X; Qian M; Liu M Mol Cancer Res; 2010 Nov; 8(11):1477-88. PubMed ID: 21047770 [TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 Expression Through the 67-κDa Laminin Receptor and the TLR4/MAPK/NF-κB Signalling Pathway in Lipopolysaccharide-Induced Macrophages. Li YF; Wang H; Fan Y; Shi HJ; Wang QM; Chen BR; Khurwolah MR; Long QQ; Wang SB; Wang ZM; Wang LS Cell Physiol Biochem; 2017; 43(3):926-936. PubMed ID: 28957799 [TBL] [Abstract][Full Text] [Related]
14. Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. Maeda-Yamamoto M; Suzuki N; Sawai Y; Miyase T; Sano M; Hashimoto-Ohta A; Isemura M J Agric Food Chem; 2003 Mar; 51(7):1858-63. PubMed ID: 12643642 [TBL] [Abstract][Full Text] [Related]
15. Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. Sil H; Sen T; Chatterjee A Oncol Res; 2011; 19(7):335-48. PubMed ID: 21936403 [TBL] [Abstract][Full Text] [Related]
16. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. Byun HJ; Hong IK; Kim E; Jin YJ; Jeoung DI; Hahn JH; Kim YM; Park SH; Lee H J Biol Chem; 2006 Nov; 281(46):34833-47. PubMed ID: 16984917 [TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of NF-κB‑mediated matrix metalloproteinase-9 expression. Qin J; Wang Y; Bai Y; Yang K; Mao Q; Lin Y; Kong D; Zheng X; Xie L Mol Med Rep; 2012 Nov; 6(5):1040-4. PubMed ID: 22941057 [TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226 [TBL] [Abstract][Full Text] [Related]
19. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. Ahmed S; Wang N; Lalonde M; Goldberg VM; Haqqi TM J Pharmacol Exp Ther; 2004 Feb; 308(2):767-73. PubMed ID: 14600251 [TBL] [Abstract][Full Text] [Related]
20. Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-κB signaling pathways. Jiang Q; Pan Y; Cheng Y; Li H; Liu D; Li H Oncol Rep; 2016 Jul; 36(1):253-62. PubMed ID: 27175819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]